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Epithelial–mesenchymal transitionN-myc downstream-regulated gene 1 (NDRG1) has been implicated in tumorigenesis andmetastasis in different
cancers. However, its role in nasopharyngeal carcinoma remains unknown. We found that NDRG1 expression
level was high in nasopharyngeal cancer 5-8F cells but low in 5-8F-LN cells with lymphatic metastasis potential.
Knockdown of NDRG1 by shRNA promoted 5-8F cell proliferation,migration, and invasion in vitro and its tumor-
igenesis in vivo. Moreover, NDRG1 deﬁciency induced an epithelial–mesenchymal transition (EMT) of 5-8F cells
as shown by an attenuation of E-cadherin and an induction of N-cadherin and vimentin expression. NDRG1
knockdown also enhanced Smad2 expression and phosphorylation. Smad2 signaling was attenuated in 5-8F
cells but was signiﬁcantly activated in 5-8F-LN cells. Knockdown of Smad2 restored E-cadherin but attenuated
N-cadherin expression in NDRG1-deﬁcient 5-8F cells, suggesting a reduction of EMT. Consistently, blockade of
Smad2 in 5-8F-LN cells increased E-cadherin while diminishing N-cadherin and vimentin expression. These
data indicate that Smad2 mediates the NDRG1 deﬁciency-induced EMT of 5-8F cells. In tumors derived from
NDRG1-deﬁcient 5-8F cells, E-cadherin expression was inhibited while vimentin and Smad2 were increased in
a large number of cancer cells. Most importantly, NDRG1 expression was attenuated in human nasopharyngeal
carcinoma tissues, resulted in a lower survival rate in patients. The NDRG1was further decreased in the detached
nasopharyngeal cancer cells, whichwas associatedwith a further reduced survival rate in patients with lymphat-
ic metastasis. Taken together, these results demonstrated that NDRG1 prevents nasopharyngeal tumorigenesis
and metastasis via inhibiting Smad2-mediated EMT of nasopharyngeal cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Nasopharyngeal carcinoma (NPC) is one type of head and neck
cancers with very different epidemiology, pathology, clinical features,
treatment and outcome compared with other head and neck cancers.
The local recurrences and metastasis of NPC are common though it
has a relatively high sensitivity to radiation therapy [1]. The vulnerable
populations of NPC are aged people predominantly between 40 and
60 years old [2]. Although NPC is very prevalent among the Cantonese
in Southern China where the prevalence rate is approximately 30–80/
100,000 population/per year, the incidence rate is around 1/100,000 insiology & Pharmacology, The
30602, United States.
y, Nanfang Hospital, Southern
mu.edu.cn (Z.-G. Li).America and Europe [3]. The main histological appearances of NPC are
the poorly differentiated or undifferentiated pathological alteration.
Due to the histological characteristic and the abundant lymphatic net-
work in nasopharynx, NPC exhibits highly metastatic potential than
other squamous cell carcinoma of head and neck [4]. The carcinogenesis
of NPC is a complicated process involving multiple genetic and epige-
netic events. Therefore, it is important to examine the genes/proteins
altered during the nasopharyngeal carcinogenesis in order to identify
potential targets for develop novel treatments against this disease.
HumanN-myc downstream-regulated gene 1 (NDRG1) is amember
of the N-myc down-regulated gene family which belongs to the alpha/
beta hydrolase superfamily [5–7]. The 43 kDa protein encoded by this
gene is a highly conserved cytoplasmic protein involved in cell growth
arrest and proliferation, cell differentiation, DNA damage response,
heavymetal response, the hypoxia response, tumorigenesis, andmetas-
tasis [8–10]. Previous studies have shown that NDRG1 plays different
roles in different types of tumors. NDRG1 appears to serve as a putative
tumor suppressor and is down-regulated in colorectal [11,12], gastric
[13], cervical [14], ovarian [15] and prostate [16] cancers.
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regulates cancer cell proliferation, differentiation, andmetastasis. For ex-
ample, NDRG1 promotes portal vein invasion and intrahepaticmetastasis
in hepatocellular carcinomas [17]. In vitro, NDRG1 is up-regulated in
A549 lung cancer cell after exposing to hypoxia mimics, which results
in more cell proliferation and less apoptosis [10]. Furthermore, NDRG1
expression level correlates with the degree of differentiation of several
cancer tissues. NDRG1 expression in poorly differentiated carcinoma is
signiﬁcantly higher than that in well-differentiated carcinoma of the
colon [12] and liver [18]. However, the correlation between NDRG1 and
Nasopharyngeal carcinoma has not been established. Therefore, the bio-
logical functions of NDRG1 in the pathogenesis of NPC remain unknown.
We hypothesize that NDRG1 affects the differentiation, proliferation,
invasion, andmetastasis of NPC cells. Indeed,we found that NDRG1 is dif-
ferentially expressed inNPC cell line 5-8F and 5-8F-LN. NDRG1 appears to
be an important factor that maintains NPC homeostasis and thus inhibits
the development of NPC and its metastasis.
2. Materials and methods
2.1. Cell culture
Human nasopharyngeal carcinoma 5-8F cells (5-8F) and 5-8F-LN
cells with lymphatic metastasis potential (5-8F-LN) [19] were cultured
in RPMI 1640 medium supplemented with 10% FBS (Hyclone). The
cells were maintained in standard conditions (5% CO2 and 95%
atmosphere, 37 °C).
2.2. 2-Dimension gel electrophoresis (2DE) andmass spectrometry analysis
Proteinswere extracted fromNPC 5-8F cell and 5-8F-LN cells. Cell ly-
sates were cleared by centrifugation at 12,000 rpm at 4 °C for 1 h, and
the protein concentration of the supernatants was determined by the
modiﬁed Bradford method. 2DE analysis was performed as described
by the manufacturer (GE HealthCare, USA). The gels were stained with
Coomassie brilliant blue (CBB), and protein spots of interest were cut
from the gels. Then, proteins were digested with trypsin, and the pep-
tide mixtures were dried at ambient temperature and then analyzed
by MALDI-TOF–TOF (ABI4700) mass spectrometry. The spectrometry
was calibrated internally using the monoisotopic [M+ H]+ ions of the
peptide standards of trypsin. Protein spots were identiﬁed by the
MASCOT searching program in IPI_human_v3.49 database.
2.3. Adenoviral vector construction
NDRG1 adenoviral vector was constructed and the viruses were pu-
riﬁed as described previously [20]. NDRG1 short hairpin RNA (shRNA)
target sequence was ACC CCG GCA ACC TGC ACC TGT TCA TCA.
Double-stranded DNA coding NDRG1 shRNA was cloned into pRNAT-
H1.1 Adeno shuttle vector containing a cGFP marker (Genscript). Ade-
novirus was packaged in Ad-293 cells (Agilent) and puriﬁed by CsCl2
gradient ultracentrifugation. Viral particle titer was determined by
plaque assay. For adenoviral transduction, 5-8F cell was transduced
with 100 multiplicity of infection of adenoviral control or shRNA for
24–48 h.
2.4. Transfection of siRNAs against Smad2 and Smad3
SiRNAs were transfected into cells using lipofectamine 2000 trans-
fection reagent (Life Technologies) by following the manufacturer's
instructions. Two different siRNAs against Smad2 (siSmad2) or Smad3
(siSmad3) were synthesized by Shanghai GenePharma. Sense se-
quences for Smad2 siRNAs are CAG GCU GUA AUC UGA AGA UTT
(siSmad2-1) and GAA GAG GAG UGC GCU UAU ATT (siSmad2-2).
Sense sequences for Smad3 siRNAs are GCG UGA AUC CCU ACC ACU
ATT (siSmad3-1) and GCC AUC CAU GAC UGU GGA UTT (siSmad3-2).SiRNA knockdown efﬁciency was veriﬁed bywestern blotting detection
of Smad2 and Smad3 protein expression.
2.5. Reverse transcriptase-polymerase chain reaction (PCR) and real-time
reverse transcriptase-polymerase chain reaction (qPCR)
Total RNAs were isolated from the cells using TRIzol reagents
(Takara, Cat # 9108). 10 μg of RNA from each sample was added to
20 μl reaction mixture, and cDNA was synthesized using PrimeScript™
RT reagent Kit with genomic DNA Eraser (Takara, Cat# RR047A). qPCR
wasperformedusing SYBR®Premix Ex Taq™ (Tli RNaseH Plus) (Takara,
Cat# RR420A) to detect NDRG1 mRNA expression. Glyceraldehyde-3
phosphate dehydrogenase (GAPDH) was used as an internal control.
The primers for human NDRG1 were 5′-ACA ACC CTG AGA TGG TGG
AG-3′ (forward) and 5′-TGT GGA CCA CTT CCA CGT TA-3′ (reverse).
The primers for human TGF-β1 were 5′-AAG GAC CTC GGC TGG AAG
TG-3′ (forward) and 5′-CCC GGG TTA TGC TGG TTG TA-3′ (reverse).
The primers for human GAPDH were 5′-ACA GTC AGC CGC ATC TTC
TT-3′ (forward) and 5′-GAC AAG CTT CCC GTT CTC AG-3′ (reverse).
The NDRG1 and TGF-β expression was normalized to GAPDH [21,22].
2.6. Western blotting
Cell lysateswere prepared by a SDS lysis solution. Protein concentra-
tion was measured using a BCA protein assay kit. Equal amount of pro-
teinwas separated by electrophoresis on a 10% SDS-polyacrylamide gel.
The proteins were electrotransferred from the gel to nitrocellulose
membrane. The membrane was blocked with 5% non-fat milk solution
for 1 h, and then was incubated with primary monoclonal antibody
against NDRG1 (Abcam), E-cadherin (Cell signaling), vimentin (Cell
Signaling), N-cadherin (Cell Signaling), Smad2 (Cell Signaling),
p-Smad2 (CST), Smad3 (Epitomics), p-Smad3 (Epitomics) at 4 °C over-
night. α-Tubulin was used as an internal control. After washing with
TBS-T, the membrane was incubated with secondary antibodies against
goat or mouse immunoglobulin G. The membrane was washed and de-
tected by the enhanced chemiluminescence (ECL) detection system
(Thermo) according to the manufacturer's instructions.
2.7. Immunohistochemistry and immunoﬂuorescence
Following antigen retrieval, 5 μm-thick tissue sections were
incubated with NDRG1 (Abcam), E-cadherin, vimentin, Smad2, or ki67
antibody (Santa Cruz) at 4 °C overnight. For negative control, the prima-
ry antibody was replaced with normal nonimmune serum. Cytoplasmic
staining was regarded as a positive signal. The degree of staining in the
sections was observed and scored independently by 2 pathologists. The
percentage of NDRG1 positive cells varied from 0% to 100%, which was
recorded on the following 4-point scale: 1 (0–25%), 2 (26–50%), 3
(51–75%), and4 (76–100%). The intensity of cytoplasmic staining varied
fromweak to strong. The cells at each intensity of stainingwere record-
ed on the following 4-point scale: 0 (no staining), 1 (weak staining, light
yellow), 2 (moderate staining, yellowish brown), and 3 (strong staining,
brown). Tumor tissues with an intensity score ≧2 in which ≥50% of
malignant cells were stained positive for NDRG1 were classiﬁed
as tumors with high expression (or overexpression), and tumor
tissues with an intensity score b2 or of which b50% of malignant cells
were stained positive for NDRG1 were classiﬁed as tumors with low
expression [23].
For immunoﬂuorescence staining of cultured cells, cells seeded on
confocal dish were transfected with adenoviral vectors. 48 h later,
cells were ﬁxed with 4% paraformaldehyde for 30 min and perme-
abilized with 0.5% Triton X-100 for 10 min at room temperature. The
cells were then incubated with primary antibodies at 4 °C overnight
followed by washes with PBS and incubation with ﬂuorescent second-
ary antibody in dark at room temperature for 1 h. After ﬁnal washes
with PBS, the confocal dish was mounted using an anti-fade mounting
1878 Z.-Y. Hu et al. / Biochimica et Biophysica Acta 1852 (2015) 1876–1886solution containing 4, 6-diamidino-2-phenylindole (DAPI). The staining
was examined, and images were captured using an Olympus Confocal
laser scanning microscopy FV1200.
2.8. In vitro cell growth assay
Cells were seeded in 96-well plates at 1 × 103/well and incubated for
1, 2, 3, 4 or 5 days. Cell proliferation was evaluated using Cell Counting
Kit-8 (CCK-8, Dojindo, USA) according to manufacturer's instructions.
Brieﬂy, 10 μl of CCK-8 solution was added to culture medium, and incu-
bated for 2 h. The absorbance at 450nmwavelengthwasmeasuredwith
a reference wavelength of 650 nm. All experiments were repeated for
three times.
2.9. Colony formation assay
About 2 × 102 cells were added to eachwell in a 6-well culture plate,
and each group contained three wells. After incubation at 37 °C for
two weeks, the cells were washed twice with PBS and stained with
hematoxylin solution. The number of colonies containing ≧50 cells
was counted under a microscope.
2.10. Scratch wound-healing assay
Cells were seeded in 24-well plates at a density of 1 × 105 cells/well
and cultured in standard conditions until 80–90% conﬂuence and treat-
ed with mitomycin C (10 μg/ml) during the wound healing assay. The
cell migration was assessed by measuring the movement of cells into
the acellular area created by a sterile insert. The wound closure was
observed after 48 h.
2.11. Transwell in vitro migration assays
5-8F cells in serum-free medium (200 μl containing 1 × 105 cells)
were added to the top chamber of Transwell chambers (Corning Star,
Cambridge, Massachusetts, USA) of pore size 8 mm. The bottom cham-
ber contained medium with 10% FBS as a chemoattractant. The cells
were incubated at 37 °C for 36 h to allow migration. Cells that had mi-
grated through the membrane and attached to the lower surface of
the membrane were stained using a ﬁxative/staining solution contain-
ing 0.1% crystal violet, 1% formalin and 20% ethanol for visualization
and quantiﬁed under a microscope. The experiments were repeated
for three times.
2.12. Animals and in vivo tumor growth assay
Nudemiceweremaintained in a barrier facility in racks ﬁlteredwith
high-efﬁciency particulate air ﬁlter. The animals were fed with an
autoclaved laboratory rodent diet. The mice in this study were
purchased from the Experimental Animal Centre of Southern Medical
University, which is certiﬁed by the Guangdong Provincial Bureau of
Science, and the Permission number is SCXK2011-0015. All animal
experiments involving ethical and humane treatment were under a
license from the Guangdong Provincial Bureau of Science and all
procedures were approved by the Institutional Animal Care and Use
Committee of the Southern Medical University.
For in vivo tumor growth assay, 5-8F cells were harvested by
trypsinization, washed twice with cold serum-free medium, and
re-suspended with serum-free medium. To evaluate cancer growth
in vivo, control or NDRG1 shRNA-transduced 5-8F cells (2 × 106) were
subcutaneously injected into the left and right ﬂank of 8 nude mice.
The tumors were removed 22 days later to analyze the tumor growth
by measuring the tumor sizes and observing the histology of the
tumor tissues.2.13. Human NPC tissues
Eighty-three parafﬁn-embedded human NPC samples were obtain-
ed from patients who were diagnosed with NPC between June 1996
and June 1999 in the Department of Pathology, Southern Medical
University-afﬁliated Hospital. The histology diagnosis of the disease
was determined according to the criteria of theWorld Health Organiza-
tion [24]. Pathologic staging was determined according to the current
International Union Against Cancer tumor-lymph node-metastasis clas-
siﬁcation [25]. The studies were approved by the University Ethical
Committee of Southern Medical University.
2.14. Statistical analysis
All statistical analyseswere performed using the SPSS 16.0 statistical
software. The signiﬁcance of correlation between the expression of
NDRG1 and histopathological factors was determined using Pearson x2
test. Survival curves were plotted by Kaplan–Meier method and com-
pared by log-rank test. Comparisons between groups were performed
with a 2-tailed paired Student's t test. P values b 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. NDRG1 protein was differentially expressed in NPC 5-8F from 5-8F-LN
cells
To identify proteins differentially expressed inNPC 5-8F and 5-8F-LN
cells with stable lymphatic metastasis potential [19], 2DE was
performed, and differential protein spots were successfully identiﬁed
by MALDI-TOF–TOF. We identiﬁed 42 different protein spots. Mass
spectrum identiﬁcation was performed in 11 differential protein spots
(Supplemental Table S1). We found that NDRG1 protein was expressed
very differently in 5-8F compared to 5-8F LN cells (Table S1 and Fig. 1A).
TheNDRG1 levelsweremuchhigher in 5-8F than in 5-8F-LN. To conﬁrm
its differential expression,we extracted the proteins from both 5-8F and
5-8F-LN and detected NDRG1 protein and mRNA levels in these two
cells. As shown in Fig. 1B–D, 5-8F expressed a much higher level of
NDRG1 compared to 5-8F-LN.
3.2. NDRG1 inhibited NPC 5-8F cell proliferation, migration, and invasion
NDRG1 has been found to either promote or inhibit the proliferation
of different cancer cells [10,13,26]. To investigate the potential role of
NDRG1 in the development of NPC, we used shRNA to knock down
NDRG1 in 5-8F cells (Fig. 2A) and performed CCK8 proliferation assay
and colony formation assay to detect NPC proliferation. As shown in
Fig. 2B–C, knockdown of NDRG1 promoted NPC growth and colony
formation. These data indicate that NDRG1may play a role in inhibiting
the growth of NPC tumor.
Since NDRG1 was expressed in a greater level in 5-8F than 5-8F-LN,
and 5-8F-LN cells have a lymphatic metastasis potential, we speculated
that the reduction of NDRG1 in 5-8F-LNmay be involved in NPCmetas-
tasis. Thus, we tested if NDRG1 affects NPC migration and invasion by
knocking down NDRG1 in 5-8F cells. As shown in Fig. 2D–F, blockade
of NDRG1 indeed increased NPC cell migration (Fig. 2D–E) and invasion
(Fig. 2F), suggesting that NDRG1 may play a role NPC metastasis.
3.3. Down-regulation of NDRG1 promoted the growth of 5-8F-derived NPC
tumor in vivo
Since knockdown of NDRG1 promoted NPC 5-8F cell proliferation
in vitro, we sought to determine if NDRG1 is important for NPC tumor
growth in vivo. Thus, we subcutaneously injected 5-8F cells transduced
with control or NDRG1 shRNA adenoviral vector into 16 nude
mice (8 mice/group). Tumors were removed 22 days after the cell
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Fig. 2. Knockdown of NDRG1 promoted the proliferation, migration and invasion of 5-8F cells. (A) Western blot analysis of NDRG1 protein expression in cells treated with scramble
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1880 Z.-Y. Hu et al. / Biochimica et Biophysica Acta 1852 (2015) 1876–1886implantation. As shown in Fig. 3A, knockdown of NDRG1 inhibited the
overall growth of tumors derived from 5-8F cells. Statistical analysis
showed a signiﬁcant difference in the mean tumor sizes between the
control and NDRG1-blocked 5-8F-derived tumors (Fig. 3B). To test if
NDRG1 indeed inhibited 5-8F cell growth in vivo, we detected the cell
proliferation marker Ki-67 expression in the NPC tumors. As shown in
Fig. 3C, knockdown of NDRG1 signiﬁcantly increased the number of
tumor cells expressing Ki-67, suggesting that NDRG1 attenuates NPC
cell proliferation in vivo. In addition, we found that knockdown of
NDRG1 changed the tumor cell morphology in vivo. The NDRG1-
shRNA-transduced cells-derived tumor cells appeared to be smaller
compared to the control tumor cells, suggesting that knockdown of
NDRG1 may cause an alteration of tumor cell morphology (Fig. 3C,
H&E staining and D, upper panel), consistentwith the lymphaticmetas-
tasis potential of NDRG1-downregulated 5-8F-LN cells.3.4. NDRG1 expression reversely correlated with human NPC development,
metastasis and patient survival rate
To explore if there is a correlation betweenNDRG1 level andNPC de-
velopment in human, we analyzed 83 human patient NPC samples and
found that 37 out of 83 parafﬁn-embedded NPC samples had normal
squamous epithelium adjacent to NPC, which allowed us to compare
the NDRG1 expression between the normal and NPC tissues. 35 of
these samples exhibited a much higher NDRG1 expression level in nor-
mal tissues than the corresponding NPC tissues (Fig. 4A–B, left panels),
suggesting that NDRG1 level may be important for maintaining naso-
pharyngeal cell homeostasis.
Since knockdown of NDRG1 caused increasedNPCmigration and in-
vasion in vitro, we examined the correlation of NDRG1 level with NPC
metastasis. Morphometric analyses identiﬁed some sporadic detachedH&E
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to the expression in normal tissue or the carcinoma nest. *P b 0.01 compared to normal tissue or carcinoma nest, n = 35. (C) Overall survival rate of patients who had nasopharyngeal
carcinoma with a low level of NDRG1 expression in tumors (n = 55) was much lower compared to those who had a high level of NDRG1 expression (n = 28). Kaplan–Meier curves
with univariate analyses (log-rank) were shown. P = 0.016. (D) Overall survival rate of nasopharyngeal carcinoma patients with lymphatic metastasis (n = 39) was signiﬁcantly
lower than the patients without lymphatic metastasis (n = 44). P = 0.005. P values were calculated by using log-rank tests.
1881Z.-Y. Hu et al. / Biochimica et Biophysica Acta 1852 (2015) 1876–1886involved in the EMT of NPC cells, a process implicated in metastasis of a
large number of tumors [27–29]. The key characteristic of EMT is the re-
duction of membrane E-cadherin alongwith an increased expression of
neuronal cadherin (N-cadherin) and other mesenchymal markers such
as vimentin [30–32]. We found that knockdown of NDRG1 in 5-8F cells
signiﬁcantly decreased the expression of E-cadherin while increased N-
cadherin and vimentin protein expression (Fig. 5A–C), indicating that
down-regulation of NDRG1 induced an EMT of NPC.
It is known that TGF-β signaling plays a very important role in EMT
[33]. Thus, we tested if knockdown of NDRG1 affects Smad2 or Smad3
expression and activation. As shown in Fig. 5D, blockade of NDRG1 ex-
pression in 5-8F cells increased Smad2 expression and its phosphoryla-
tion. Knockdownof NDRG1 slightly increased Smad3 expression but not
the Smad3 phosphorylation (Fig. 5D-E), suggesting that NDRG1 mayTable 1
Expression of NDRG1 in patients with nasopharyngeal carcinoma.
Characteristic NDRG1 expression:
No. of patients (%)
P
High Low
Age (y) ≧55 8 (28.6) 20 (71.4) 0.385
b55 19 (34.5) 36 (65.5)
Dukes 1 and 2 14 (38.9) 22 (61.1) 0.262
3 and 4 14 (29.8) 33 (70.2)
Lymphatic metastasis Yes 5 (12.8) 34 (87.2) 0.001
No 23 (52.3) 21 (47.7)
Distant metastasis Yes 0 (0) 9 (100) 0.027
No 26 (34.1) 48 (64.9)regulate NPC EMT by modulating Smad2 signaling. Since 5-8F-LN cells
had a much lower level of NDRG1 compared to 5-8F cells (Fig. 1B–D),
we compared the Smad2 signaling in these two cells. As shown in
Fig. 5F–G, 5-8F-LN expressed a much higher level of Smad2 and exhib-
ited a stronger Smad2 activation as compared to that in 5-8F cells, con-
sistentwith the effect of NDRG1 knockdown on Smad2 phosphorylation
in 5-8F cells (Fig. 5D). Interestingly, a higher level of TGF-β1 expression
was also observed in 5-8F-LN as compared to 5-8F (Fig. S2A), suggesting
that the higher p-Smad2 level in 5-8F-LN cells may be due to a presence
of autocrine TGF-β loop. Importantly, TGF-β1 stimulation attenuated
NDGR1 expression while inducing the EMT of 5-8F cells as shown by
the decreasedE-cadherin and increasedN-cadherin andvimentin expres-
sion (Fig. S2, B–C), further indicating that NDRG1 downregulation-
induced EMT of NPC cells may be mediated by the TGF-β-activated
Smad2 signaling.
3.6. Smad2 signaling mediated NDRG1 knockdown-induced EMT of NPC
To determine if NDRG1 knockdown-induced EMT of NPC cells
indeed via Smad2 signaling, we blocked Smad2 and Smad3 expression
in NDRG1-deﬁcient 5-8F cells using two different siRNAs against
Smad2 and Smad3, respectively. We found that blockade of
Smad2 expression increased E-cadherin expression, while decreasing
N-cadherin expression (Fig. 6A–B), indicating a blockade of the EMT.
However, blockade of Smad3 expression had no signiﬁcant effect on
E-cadherin and N-cadherin expression (Supplemental Fig. S3, A–B). To
further conﬁrm the role of Smad2 in NPC EMT, we also knocked down
Smad2 and Smad3 expression in 5-8F-LN cells. Consistent with the
effect in NDRG1-deﬁcient 5-8F cells, blockade of Smad2 enhanced
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sion (Fig. 6C–D). On the contrary, blockade of Smad3 did not show
signiﬁcant effect on E-cadherin, N-cadherin, or vimentin expression
(Supplemental Fig. S3, C–D). These data demonstrated that Smad2,
but not Smad3, played an essential role in NDRG1 deﬁciency-induced
EMT of NPC.
3.7. Knockdown of NDRG1 induced EMT of NPC in vivo
Since we observed a cell morphology alteration in tumor cells
derived from NDRG1 deﬁcient 5-8F cells, we speculated that there
was an EMT in these cells. Indeed, these cells exhibited a reduction
of E-cadherin expression with an increase of vimentin expression
(Fig. 7A–B). Importantly, Smad2 expression was also increased
(Fig. 7A–B), consistent with its role in the EMT in vitro. Moreover, we
also observed a high level expression of Smad2 and vimentin with an
attenuation of E-cadherin in the detached cancer cells in human NPC
tissues (Fig. 7C–D). These data indicated that Smad2 indeed mediated
the EMT of NPC in mice or human patients, which contributed, at least
partially, to the NPC metastasis.
4. Discussion
NDRG1 is involved in cellular differentiation, cell cycle arrest, and
apoptosis, and regulates tumor growth and metastasis in various carci-
nomas [34–39]. Interestingly, depending on the types of tumors NDRG1
can be a metastasis suppressor or a facilitator [11–14,40,41]. So it is im-
portant to determine its role in NPC. NDRG1 is strongly expressed innormal nasopharyngeal tissue but signiﬁcantly reduced in NPC tumors
(Fig. 4A–B, left panels). Functionally, NDRG1 appears to be important
for maintaining nasopharyngeal cell homeostasis because reduction of
NDRG1 level caused an increased NPC proliferation in vitro (Fig. 2B–C)
and NPC tumor growth in vivo (Fig. 3A–B). Importantly, NDRG1 reduc-
tion is correlatedwith lymphaticmetastasis potential, which is support-
ed by the reduced expression of NDRG1 in 5-8F-LN cells versus 5-8F
cells (Fig. 1A–D), the lower level of NDRG1 in detached human NPC
cells comparing to the stable carcinoma cells (Fig. 4A–B, right panels),
and the low expression in human NPC with lymphatic metastasis
(Fig. 4D). Most importantly, NDRG1 level is reversely associated with
NPC patient prognosis or survival (Fig. 4C), consistent with previous re-
ports on other carcinomas showing that NDRG1 expression has a signif-
icant inverse correlation with tumor stromal invasion and lymphatic
metastasis [42,43]. Therefore, NDRG1 may serve as a valuable biomark-
er to monitor NPC development in humans.
Interestingly, instead of its suppression role in NPC and several other
carcinoma, NDRG1 promotes the development or metastasis of lung
cancer [10], colon cancer [12], and hepatocellular carcinomas [17].
One possible explanation for these opposite observations is that
NDRG1 may use different signaling pathways in different tumor cells
to regulate the tumor cell growth, migration and invasive ability. It is
known that NDRG1 can interact with several different oncogenic signal-
ing pathways such as PI3K/AKT, nuclear factor-kappaB (NF-kB), mam-
malian target of rapamycin (mTOR), and MAPK signaling pathways
[44]. Future investigation is required to identify signaling pathways by
which NDRG1 regulates the proliferation, migration and invasion of
NPC cells.
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Our data provide a link between NDRG1 and EMT of NPC,which is likely
to be one of the mechanisms regulating NPC metastasis. Knockdown of
NDRG1 blocks E-cadherin expressionwhile increasing vimentin expres-
sion both in vitro (Fig. 5A–C) and in vivo (Fig. 7A–B). The EMT is also ob-
served in human NPC tissues with lymph node metastasis (Fig. 7C–D).
These observations support that NDRG1 is ametastasis suppressor rath-
er than a metastasis promoter for NPC. EMT can be mediated by many
different proteins, but TGF-β-related factors have emerged as major in-
ducers of the transdifferentiation process in development and cancer.
Among these factors, Smad3 is considered to be the primary signaling
molecule in mediating EMT of many tumors [45–47]. However, EMT
of several cancer cells has been shown to depend on Smad2 signaling
[48,49]. Indeed, expression of activated Smad2 promotes spindle
tumor cell invasion, and a dominant negative form of Smad2 inhibits
it, suggesting that Smad2 may promote EMT in vivo [48]. NDRG1
downregulation-induced EMT of NPC cells is primarily mediated by
Smad2 (Figs. 5D–G and 6A–D), but not Smad3 signaling (Supplemental
Fig. S3, A–D). The possible explanation is that NDRG1 down-regulation
causes an increased Smad2 expression and Smad2 phosphorylation
without impacting Smad3 expression/phosphorylation. The activated
Smad2may induce the expression of downstream EMT regulators, lead-
ing to EMT of NPC cells. Smad2 may also interact with other signaling
pathways to control the gene reprogramming during EMT of NPC cells
because it is increasingly apparent that signaling pathways cooperatein the execution of EMT [33], which will be an interesting subject for
future study. The NDRG1-Smad2 pathway is likely to be dependent of
TGF-β because TGF-β induces EMT of NPC cells while inhibiting NDRG1
expression (Supplemental Fig. S2, B–C), and TGF-β expression is in-
creased in the NPC cells with lymph node metastasis potential
(Supplemental Fig. S2, A).
The role of NDRG1 in EMT of cancer cells is also supported by
other studies [30]. It has been shown that TGF-β induces the EMT
of prostate and colon cancer cells in vitro via down-regulation of
NDRG1 although NDRG1 appears to affect both Smad2 and Smad3
signaling in these cells [30]. Importantly, since iron chelators
Dp44mT and DFO are found to inhibit TGF-β-induced EMT of pros-
tate and colon cancer cells via increasing NDRG1 expression [30],
these chelators may also inhibit the EMT of NPC cells via altering
NDRG1 expression and thus may be used as potential therapeutic
agents for treating human patients. Extensive preclinical and clinical
studies are required to test the efﬁcacy and side effects of Dp44mT
and DFO because several iron chelators are known to generate cyto-
toxic radicals in addition to its antitumor activities [50]. In view of
the unique location of NPC, a local application of these chelators
may avoid a systematic cytotoxicity.
In summary, we have identiﬁedNDRG1 as a novel protein factor that
inhibits the growth and metastasis of NPC. NDRG1 appears to prevent
NPC EMT by attenuating Smad2 signaling. Moreover, since down-
regulation of NDRG1 is correlated with the lymphatic metastasis of
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marker for surveillance of NPC progression and therapeutic target in
human patients.
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